论文部分内容阅读
老年社区获得性肺炎(CAP)住院患者通常病情较重、病死率较高且造成沉重经济负担。因此,临床上需要寻求一种可有效治疗老年CAP患者的用药方案。国内外学者为此做了诸多临床研究,但仍缺乏氟喹诺酮类药物静脉应用治疗该类患者临床疗效和安全性方面的报道。2006年,Anzueto等发表的CAPRIE研究添补了此项空白。CAPRIE研究结果显示:莫西沙星治疗老年CAP患者,在各个研究亚组中均显示出其在临床疗效及安全性方面的优势。莫西沙星组临床症状好转较左氧氟沙星组更快。两种药物的不良反应发生率相似。
Inpatients with senile community-acquired pneumonia (CAP) are generally more afflicted, have a higher case fatality and cause a heavy financial burden. Therefore, there is a clinical need to find a solution that can effectively treat elderly CAP patients. Domestic and foreign scholars have done a lot of clinical research, but there is still a lack of intravenous fluoroquinolones treatment of such patients clinical efficacy and safety reports. In 2006, Anzueto and other published CAPRIE study to fill this gap. CAPRIE results show that: moxifloxacin elderly CAP patients in all study subgroups showed its clinical efficacy and safety advantages. Moxifloxacin group improved clinical symptoms than the levofloxacin group faster. Adverse reactions of both drugs were similar.